Swiss-based drug company Anavex Life Sciences Corp. announced today that they have selected FORENAP Pharma as the contract research organization for Phase 1 clinical trials of ANAVEX 2-73, the company’s lead Alzheimer’s drug candidate.
FORENAP has been involved in pre-clinical and clinical research for 20 years and is renowned for its expertise in central nervous system studies, including Alzheimer’s disease. FORENAP will perform study setup, protocol review, site monitoring and project management for the trials. Rudy Luthringer, CEO of FORENAP, said, “We look forward to running a high-quality and cost-effective program as Anavex works to confirm its pre-clinical findings in a clinical setting.”
ANAVEX 2-73 has been shown in pre-clinical testing to be neuroprotective and anti-amnesic. It is thought that the drug impacts mitochondrial dysfunction and it may be mitochondrial protective. Mitochondrial dysfunction is thought by many researchers to be one of the hallmarks of Alzheimer’s disease.
Avanex Life Sciences is approaching Alzheimer’s disease from a different angle. The company’s unique approach with their drug focuses on addressing an underlying cause of Alzheimer’s disease, unlike current drugs on the market that provide only symptomatic relief.
Dr. Herve de Kergrohen, CEO of Anavex Life Sciences, commented on the contract award to FORENAP, “The selection of a world-class contract research organization is an important milestone in our product development process and it underscores our commitment to advance ANAVEX 2-73 through Phase 1 clinical trials. We are moving forward into these trials based on the positive results of our pre-clinical testing, which demonstrated the compound’s significant disease-modifying potential and its powerful anti-amnesic and neuroprotective properties.”